Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial.

Tytuł :
Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial.
Autorzy :
McDonald AM; University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
Dobelbower MC; University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
Yang ES; University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
Clark GM; East Tennessee Radiation Oncology PC, Knoxville, Tennessee.
Jacob R; University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
Kim RY; University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
Cardan RA; University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
Popple R; University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
Nix JW; University of Alabama at Birmingham, Department of Urology, Birmingham, Alabama.
Rais-Bahrami S; University of Alabama at Birmingham, Department of Urology, Birmingham, Alabama.
Fiveash JB; University of Alabama at Birmingham, Department of Radiation Oncology, Birmingham, Alabama.
Pokaż więcej
Źródło :
Advances in radiation oncology [Adv Radiat Oncol] 2018 Sep 19; Vol. 4 (1), pp. 90-95. Date of Electronic Publication: 2018 Sep 19 (Print Publication: 2019).
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Original Publication: [Philadelphia, PA] : Elsevier Inc., [2016]-
References :
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105. (PMID: 17336216)
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82. (PMID: 21300474)
Acta Oncol. 2013 Aug;52(6):1181-8. (PMID: 23544356)
Radiat Oncol. 2013 Apr 09;8:84. (PMID: 23570391)
J Urol. 2013 Nov;190(5):1721-1727. (PMID: 23727310)
Radiother Oncol. 2013 Jun;107(3):274-81. (PMID: 23791306)
Radiat Oncol. 2013 Oct 02;8:228. (PMID: 24088319)
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):406-15. (PMID: 24685447)
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):509-17. (PMID: 24929162)
Cancer Med. 2014 Oct;3(5):1313-21. (PMID: 24976538)
Clin Oncol (R Coll Radiol). 2014 Dec;26(12):757-61. (PMID: 25193299)
Front Oncol. 2014 Sep 02;4:240. (PMID: 25229051)
Front Oncol. 2014 Nov 14;4:279. (PMID: 25452933)
Front Oncol. 2015 Jan 22;4:369. (PMID: 25657929)
Radiat Oncol. 2015 Feb 19;10:44. (PMID: 25890265)
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):971-977. (PMID: 26054865)
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30. (PMID: 26733552)
Cureus. 2015 Dec 04;7(12):e395. (PMID: 26798571)
Eur J Cancer. 2016 May;59:142-151. (PMID: 27035363)
Radiat Oncol J. 2016 Dec;34(4):260-264. (PMID: 27306777)
J Urol. 2017 Feb;197(2):320-326. (PMID: 27484386)
Am J Surg Pathol. 2017 Jan;41(1):101-105. (PMID: 27574875)
Front Oncol. 2016 Aug 29;6:185. (PMID: 27622157)
J Med Radiat Sci. 2017 Sep;64(3):180-187. (PMID: 28271639)
Pract Radiat Oncol. 2017 Mar - Apr;7(2):e109-e116. (PMID: 28274401)
Acta Oncol. 2017 Jul;56(7):978-983. (PMID: 28514930)
Transl Androl Urol. 2017 Jun;6(3):406-412. (PMID: 28725582)
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):287-295. (PMID: 29913254)
Entry Date(s) :
Date Created: 20190202 Latest Revision: 20201001
Update Code :
20210210
PubMed Central ID :
PMC6349624
DOI :
10.1016/j.adro.2018.09.007
PMID :
30706015
Czasopismo naukowe
Purpose: This study aimed to report the early toxicity results of a prospective clinical trial of prostate stereotactic body radiation therapy (SBRT) to the entire prostate with a simultaneous integrated boost (SIB) to magnetic resonance imaging (MRI)-defined focal lesions.
Methods and Materials: Eligible patients included men with biopsy-proven prostate stage T1c to T2c adenocarcinoma, a Gleason score ≤7, and prostate-specific antigen values of ≤20 ng/mL, who had at least 1 focal lesion visible on MRI and a total prostate volume no greater than 120 cm 3 . SBRT consisted of a dose of 36.25 Gy to the entire prostate with an SIB of 40 Gy to the MRI-defined lesions, delivered in 5 fractions. The primary purpose of the study was to confirm the feasibility of treatment planning/delivery and to estimate the rate of urinary retention requiring placement of a Foley catheter within 90 days of treatment. This study was to be considered successful if urinary retention occurred in no more than 15% of cases, with a planned enrollment of at least 25 patients.
Results: A total of 26 men were enrolled, and all underwent SBRT as planned. Twenty patients (77%) had intermediate-risk features, and the remainder were low risk. A treatment plan that met the protocol-defined goals for all cases was developed. Two patients (7.7%) developed acute urinary symptoms that required the temporary placement of a Foley catheter. No grade 3+ toxicity events were observed.
Conclusions: Planning and delivery of prostate SBRT with a whole prostate dose of 36.25 Gy and a focal 40 Gy SIB is feasible. Early follow-up suggests that this treatment is not associated with undue morbidity.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies